Overview
Adeno-associated viral (AAV) vectors provide many advantages such as their lack of pathogenicity and toxicity, long-term transgene expression, and safety profiles. However, large-scale manufacturing remains inconsistent in the cell & gene industry. This article details how developers should consider independent, innovative processes in-house for producing high-quality, high-productivity AAVs, and the opportunities of the AGC Biologics custom platform to support their needs.
